Authors

Latest:

Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple Myeloma

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Vlad Gabriel Zaha, MD, PhD

Latest:

Dr Zaha on the Risk of Cardiovascular Toxicity in Patients With Lung Cancer

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.

Ira Braunschweig, MD

Latest:

Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in Lymphoma

Ira Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.

M. Michele Blackwood, MD, FACS

Latest:

Dr Blackwood on the Significance of Early Breast Cancer Screenings

M. Michele Blackwood, MD, FACS, discusses the significance of early cancer screenings.

Jennifer M. King, MD

Latest:

Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular Cancer

Jennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.

Michelle Shiller, DO

Latest:

Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

Drs Dietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex testing.

University of Chicago Medicine

Latest:

UChicago Medicine Among the First to Offer Histotripsy for Liver Tumors

The University of Chicago Medicine treats patients with histotripsy, a technology that uses ultrasound energy to destroy liver tumors.

Amanda Cass, PharmD, BCPS, BCOP

Latest:

Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

Ashwin Kishtagari, MD

Latest:

Dr Kishtagari on JAK Inhibitor Selection for Myelofibrosis in the Community Setting

Ashwin Kishtagari, MD, discusses the selection process of JAK inhibitors for patients with myelofibrosis being treated in a community setting.

Catherine Ann Shu, MD

Latest:

Dr Shu on Advances in Adjuvant Therapy For Early-Stage NSCLC

Catherine Ann Shu, MD, discusses key therapeutic advances in the adjuvant setting for patients with early-stage non–small cell lung cancer.

Meghana Kesireddy, MBBS

Latest:

Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast Cancer

Meghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.

Mojun Zhu, MD

Latest:

Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract Cancer

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

Erminia Massarelli, MD, PhD, MS

Latest:

Dr Massarelli on Using Selpercatinib and Pralsetinib in Treating Advanced Non-Small Cell Lung Cancer

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Neel P. Chudgar, MD

Latest:

Dr Chudgar on Defining Resectability in NSCLC

Neel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.

Gautam Jha, MD

Latest:

Dr Jha on Community Accrual to the ECLIPSE Trial in Prostate Cancer

Gautam Jha, MD, discusses collaborative efforts between community and academic oncologists to accrue patients to the ECLIPSE trial.

Tomer Mark, MD

Latest:

Dr. Mark on Questions Regarding Sequencing in Multiple Myeloma

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

David Gerber, MD

Latest:

How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD

Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.

Puja S. Venkat

Latest:

Dr. Venkat on Unmet Needs in Ovarian Cancer

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer.

Yasir Y. Elamin, MD

Latest:

BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC

Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.

Bilal A. Siddiqui, MD

Latest:

Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPC

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.